Order results by:
| Issue | Title | |
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... Cladribine tablets are a new drug for the immune reconstitution therapy of highly active multiple ..." | ||
| Vol 16, No 5 (2024) | Efficacy and safety of cladribine tablets in multiple sclerosis in real-world clinical practice | Abstract similar documents |
| A. N. Peshkin, S. V. Kotov, G. T. Toniya, M. V. Sutormin, A. F. Eltayoury | ||
| "... Cladribine has a well-defined activity against lymphocytes, leading to their selective depletion ..." | ||
| Vol 14, No 1 (2022) | Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... Objective: to evaluate the efficacy and safety of cladribine tablets as a treatment for immune ..." | ||
| Vol 16, No 3 (2024) | Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra | Abstract similar documents |
| A. A. Sokolova, L. I. Anischenko, L. S. Zemlyanushin, E. A. Rubtsova | ||
| "... Cladribine is a tablet preparation for the treatment of relapsing-remitting multiple sclerosis ..." | ||
| Vol 12, No 3 (2020) | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis | Abstract similar documents |
| K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina | ||
| "... participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects ..." | ||
| Vol 12, No 5 (2020) | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets | Abstract similar documents |
| N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika | ||
| "... a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets ..." | ||
| Vol 16 (2024): (Suppl. 2) | Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres | Abstract similar documents |
| A. N. Boyko, V. M. Alifirova, D. V. Pashkovskaya, E. I. Kuchina, S. A. Sivertseva, E. L. Turova, Z. A. Goncharova, O. Yu. Rudenko, Yu. Yu. Pogrebnova, F. A. Khabirov, T. I. Khaibullin, N. N. Babicheva, N. L. Khoroshilova, O. V. Dzundza, O. A. Soldatova, A. N. Belova, G. Е. Sheiko, A. Е. Makarova, N. G. Glavinskaya | ||
| "... of cladribine tablets in daily practice on the course of MS over 3–4 year observational period after immune ..." | ||
| Vol 15 (2023): (Suppl. 1) | Prolonged observation after the use of cladribine in multiple sclerosis: efficacy and safety | Abstract similar documents |
| A. D. Kukushkina, A. N. Boyko | ||
| "... of advantages, including short treatment courses with long-term effects on immune mechanisms. Cladribine tablets ..." | ||
| Vol 16, No 1S (2024): Спецвыпуск: Головная боль | Gastric stasis in migraine and the efficacy of antimigraine drugs | Abstract similar documents |
| G. R. Tabeeva, A. A. Kharitonova | ||
| "... dispersible tablets, efficacy in relieving pain and accompanying symptoms, and ease of administration make ..." | ||
| Vol 15, No 2 (2023) | Optimization of migraine attacks relief | Abstract similar documents |
| G. R. Tabeeva, A. V. Amelin, L. R. Akhmadeeva, A. B. Danilov, O. B. Doronina, M. I. Koreshkina, N. V. Latysheva, E. G. Mendelevich, I. V. Sarvilina, A. V. Sergeev, K. V. Skorobogatykh, E. G. Filatova | ||
| "... tablets, oral dispersible forms, injections, nasal sprays, rectal suppositories). Rizatriptan in the form ..." | ||
| Vol 15, No 4 (2023) | Evaluation of pharmacokinetic parameters, safety and tolerability of single and multiple doses of Vespireit®: results of phase I clinical trial. | Abstract similar documents |
| O. D. Ostroumova, M. L. Maksimov, M. V. Zamergrad, V. A. Parfenov, E. K. Zaharova, A. L. Vladykin, A. A. Globenko, A. V. Kapashin, K. A. Ishchenko | ||
| "... buspirone), prolonged-release tablets, 15 mg (JSC “Valenta Pharm”, Russia), which is being developed ..." | ||
| Vol 16, No 5 (2024) | Experience of using Russian rizatriptan 10 mg tablets in routine clinical practice: results of a multicenter post-registration observational study “OPYT” | Abstract similar documents |
| G. R. Tabeeva, A. B. Danilov, M. I. Koreshkina, E. Z. Yakupov, A. V. Amelin, А. A. Artamonov | ||
| Vol 15, No 5 (2023) | Efficacy and safety of Vespireit® (buspirone) prolonged-release tablets (PR) 15 mg in the therapy of patients with functional dizziness: results of the double-blind, placebo-controlled, multicenter, randomized, phase 3 clinical trial | Abstract similar documents |
| M. V. Zamergrad, V. A. Parfenov, A. S. Agafina, N. V. Lyamina, M. M. Gavrik, L. R. Kuchumova, E. R. Barantsevich, V. S. Krasnov, A. A. Ivanova, A. L. Vladykin, K. А. Ishchenko | ||
| "... : to evaluate the efficacy and safety of Vespireit® (INN buspirone) prolonged-release tablets 15 mg2 (JSC ..." | ||
| Vol 14, No 3 (2022) | Combined therapy for Alzheimer's disease | Abstract similar documents |
| V. V. Zakharov, A. V. Lokshina, N. V. Vakhnina | ||
| "... combination of these drugs in a single tablet once daily regimen has been shown to provide significant ..." | ||
| Vol 15, No 4 (2023) | Pharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio® | Abstract similar documents |
| A. S. Goncharov, A. V. Grigoriev, A. A. Globenko, I. S. Goncharov, K. A. Muratov, D. V. Yaroshenko, A. A. Sidorova, A. V. Kapashin, O. V. Kovchan, A. I. Bashkatova, M. A. Pasko | ||
| "... + tizanidine, extended-release tablets, 15 mg + 6 mg, JSC Valenta Pharm, Russia) taken once by healthy ..." | ||
| Vol 15, No 3 (2023) | Clinical effectiveness and safety of prolonged release form of alimemazine in patients with generalized anxiety disorder | Abstract similar documents |
| Ju. E. Azimova, Yu. P. Sivolap, K. A. Ishchenko | ||
| "... The prolonged release tablets form of alimemazine is seen as a promising agent for the long-term ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia | Abstract similar documents |
| A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, I. V. Greshnova, V. E. Nikitenkova, I. G. Lukashevich, A. V. Inzhinova, N. A. Malkova, D. S. Korobko, O. V. Boyko, I. S. Lozovskaya | ||
| "... высокоактивным РС (ВАРС), т. е. случаев РС с наличием двух и более обострений без приема специфической ..." | ||
| Vol 4, No 4 (2012) | Citicoline for ischemic stroke: ICTUS trial | Abstract similar documents |
| Vladimir Anatolyevich Parfenov | ||
| "... as one 500-mg tablet every 12 hours during 6 weeks). The results of the trial confirmed the safety ..." | ||
| Vol 13, No 6 (2021) | Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm® Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain | Abstract similar documents |
| V. A. Parfenov, E. I. Bogdanov, V. B. Laskov, N. S. Makarov, N. V. Pisova, E. A. Salina, Zh. Yu. Chefranova, L. V. Chichanovskaya | ||
| "... tablets of 150 mg (TH 150) to one tablet of PRTH 450. Objective: to evaluate the therapeutic efficacy ..." | ||
| Vol 2, No 4 (2010) | Pediatric Tenoten in therapy of childhood nocturnal enuresis | Abstract similar documents |
| G. M. Dzhanumova, A. V. Budkevich, L. B. Ivanov | ||
| "... ; Group 1) and fenibut (n = 18; Group 2). Tenoten (pediatric formulation) was given a sublingual tablet ..." | ||
| Vol 6, No 1 (2014) | The use of neurocytoprotectors to improve rehabilitation of patients after cerebrovascular accident | Abstract similar documents |
| V.V. Kovalchuk | ||
| "... received intravenous infusion of Thiocetam at a dose of 30 ml for 14 days, then 1 tablet TID for 1 month ..." | ||
| Vol 4, No 1 (2012) | Sustained-release pramipexole in the treatment of Parkinson’s disease | Abstract similar documents |
| Natalia Vladimirovna Fedorova | ||
| "... of a tablet. Both formulations contain the same active ingredient, have the similar profile of interacting ..." | ||
| Vol 12, No 6 (2020) | Nonsteroidal anti-inflammatory drugs, muscle relaxants, and B-group vitamins in the treatment of lumbar ischialgia | Abstract similar documents |
| V. A. Shirokov, A. V. Potaturko, N. L. Terekhov | ||
| "... 15-mg tablet daily for 14 days; Group 2 received IM meloxicam 15 mg daily for 3 days, followed by one ..." | ||
| Vol 14, No 5 (2022) | Safety of Mexidol® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups | Abstract similar documents |
| E. A. Ushkalova, S. K. Zyryanov, O. I. Butranova | ||
| "... and intramuscular injection, 50 mg/ml (NPK PHARMASOFT, Russia) and Mexidol® FORTE 250 film-coated tablets, 250 mg ..." | ||
| Vol 6, No 3 (2014) | Current therapy for Parkinson's disease | Abstract similar documents |
| A. V. Obukhova | ||
| "... interaction profile, but differ in the tablet release rate of the active ingredient. The advantages ..." | ||
| Vol 17, No 1 (2025) | Aggressive multiple sclerosis in the Republic of Bashkortostan | Abstract similar documents |
| K. Z. Bakhtiyarova, U. Sh. Kuzmina, O. V. Lyutov, I. D. Talipova, N. F. Akhmetgaleeva, T. R. Galiullin, M. A. Kutlubaev | ||
| "... высокоактивный РС (ВАРС) диагностирован у 8,9% от общего числа пациентов. В обеих группах преобладают женщины. В ..." | ||
| Vol 10, No 1 (2018) | Treatment of vertigo in elderly patients with chronic cerebrovascular disease | Abstract similar documents |
| S. N. Duma | ||
| "... who took betahistine 48 mg/day, intravenous Mexidol® 5.0 ml for 10 days, then 375 mg tablets daily ..." | ||
| Vol 1, No 1 (2009) | TENOTEN IN COMPLEX THERAPY FOR CEREBROVASCULAR INSUFFICIENCY IN ELDERLY PATIENTS | Abstract similar documents |
| L. D. Serova | ||
| "... of 20 patients. During 28 days, the study group patients received tenoten as a tablet thrice daily ..." | ||
| Vol 15, No 1 (2023) | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program | Abstract similar documents |
| E. Y. Solovieva, P. R. Kamchatnov, L. B. Novikova, O. A. Kicherova, N. M. Khasanova | ||
| "... inclusive (mean age 63.6±8.8 years) with MCI and CVD, they were prescribed Prospecta, two tablets twice ..." | ||
| Vol 12, No 3 (2020) | Features of the pathogenesis, diagnosis, and treatment of panic attacks in young people | Abstract similar documents |
| M. L. Chukhlovina | ||
| "... ) as a 15-mg tablet thrice daily for 8 weeks; 2) 17 patients who were prescribed only standard therapy ..." | ||
| Vol 13, No 1 (2021) | Evaluation of the efficacy and tolerability of naftidrofuryl in the therapy of chronic cerebral ischemia | Abstract similar documents |
| M. N. Dadasheva, I. A. Zolotovskaya, R. V. Gorenkov, K. N. Dadasheva, D. I. Lebedeva | ||
| "... and received its full cycle. The patients were prescribed naftidrofuryl at a dose of 100 mg (2 tablets) thrice ..." | ||
| Vol 12, No 2 (2020) | Efficacy of tolperisone versus meloxicam in the treatment of nonspecific acute neck pain | Abstract similar documents |
| K. V. Skorobogatykh, Yu. E. Azimova | ||
| "... and 18 formed Group 2. Group 1 was prescribed tolperisone (Calmirex) as tablets: 150 mg/day on day 1, 300 ..." | ||
| Vol 15, No 6 (2023) | NOVEMA® NIGHT (diphenhydramine + naproxen) in patients with pain and insomnia: results of a multicenter non-interventional observational study | Abstract similar documents |
| A. B. Danilov, A. A. Pilipovich, M. V. Pyastolova | ||
| "... 275 mg, 1 tablet in the morning and diphenhydramine 25 mg + naproxen 220 mg (NOVEMA® NIGHT) for 5 days ..." | ||
| Vol 16, No 4 (2024) | Treatment of post-traumatic cognitive disorders and asthenia: results of an observational study | Abstract similar documents |
| P. R. Kamchatnov, O. Yu. Tsarapkina, N. G. Malyukova, A. V. Miretskaya, E. F. Danshina, L. A. Skipetrova, R. A. Cheremin | ||
| "... 1 tablet of Prospekta twice daily for 4 weeks. Cognitive functions, particularly the speed ..." | ||
| Vol 14, No 2 (2022) | Possibilities nootropic drugs in non-demented patients with vascular cognitive disorders | Abstract similar documents |
| M. N. Dadasheva, R. V. Gorenkov, V. A. Kruglov, K. N. Dadasheva, D. I. Lebedeva | ||
| "... recieved omberacetam 10 mg 2 times per day, the 2nd group – piracetam/cinnarizine 400/25 mg (1 tablet) 3 ..." | ||
| Vol 16, No 3 (2024) | Diffusion tensor tomography with tractography in assessment of the pyramidal system in patients with highly active multiple sclerosis | Abstract similar documents |
| A. N. Peshkin, G. T. Toniya, E. A. Stepanova, V. Yu. Lizhdvoi, S. V. Kotov | ||
| "... склерозом (ВАРС) в период переключения терапии в связи с неоптимальным ответом на лечение с препаратов ..." | ||
| Vol 13, No 4 (2021) | Fatigue and cognitive impairment in post-COVID syndrome: possible treatment approaches | Abstract similar documents |
| A. N. Bogolepova, N. A. Osinovskaya, E. A. Kovalenko, E. V. Makhnovich | ||
| "... tablet three times per day). Patients with CI (mean MoCA score ≤25 points; n=50) were prescribed ..." | ||
| Vol 17, No 4 (2025) | The role of central vein sign in differential diagnostics of neuromyelitis optica spectrum disorders and multiple sclerosis | Abstract similar documents |
| S. V. Kotov, E. S. Novikova, G. T. Tonya, A. S. Kotov | ||
| "... мужчин и 9 женщин), из них девять пациентов с высокоактивным течением РС (ВАРС), четыре – с ЗСОНМ с ..." | ||
| Vol 16, No 4 (2024) | Functional dizziness: from diagnostic criteria to clinical profiles and therapy. Expert consensus | Abstract similar documents |
| M. V. Zamergrad, V. A. Parfenov, O. D. Ostroumova, A. L. Guseva, O. V. Zaytseva, Yu. P. Sivolap, I. V. Kukes, V. A. Voronov | ||
| "... psychotherapy and vestibular rehabilitation methods. The use of buspirone prolonged-release tablets (Vespirate ..." | ||
| Vol 17, No 4 (2025) | Pregnancy during therapy with teriflunomide. A clinical case of accelerated elimination of teriflunomide | Abstract similar documents |
| D. M. Yakushin, S. V. Kotov, T. I. Yakushina | ||
| "... (400 tablets per day) is fraught with undesirable side effects in the form of constipation, diarrhoea ..." | ||
| Vol 12, No 1 (2020) | Comparative efficacy and tolerance of centrally acting muscle relaxants in elderly patients with nonspecific musculoskeletal pain | Abstract similar documents |
| R. V. Gorenkov, M. N. Dadasheva, I. A. Zolotovskaya, V. A. Kruglov | ||
| "... took a muscle relaxant as tablets for 15 days: Group 1 received the Russian drug tolperisone (calmyrex ..." | ||
| Vol 1, No 3-4 (2009) | RUSSIAN OBSERVATIONAL SURVEY OF THE SHORT-TERM EFFICACY AND TOLERABILITY OF SUSTAINED-RELEASE SODIUM VALPROATE (DEPAKINE CHRONOSPHERA®) AS A FIRST-LINE DRUG IN THE TREATMENT OF EPILEPSY | Abstract similar documents |
| E. D. Belousova, A. Yu. Ermakov | ||
| "... and older patients who have difficulties in taking the drug as tablets, the study group comprised children ..." | ||
| Vol 10, No 2 (2018) | Post-stroke dysphagia: novel treatment approaches | Abstract similar documents |
| M. M. Tanashyan, E. S. Berdnikovich, O. V. Lagoda | ||
| "... ; moderate dysarthria was also seen in 15 patients. Vinpocetine (Cavinton®) and its dispersible tablets ..." | ||
| 1 - 43 of 43 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
